Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.